Tools

Search

Explore

Videos Channels Figures

Atmrix

About

Tools

Search

Explore

Videos Channels Figures

Atmrix

About

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

Biotech fundraising is increasingly resembling traditional paths seen in software, with many funds showing interest in innovative science companies.

Video

YC

Elizabeth Iorns on Biotech Companies in YC

@ Y Combinator

Elizabeth Iorns on Biotech Companies in YC

09/14/17

Related Takeaways

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

There is a growing interest from early-stage technology investors in funding biotech companies, with many successfully raising significant seed funding.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

Successful biotech funds often incubate ideas internally before spinning them out as independent companies, which has proven effective in the industry.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

There is a growing trend of former students starting biotech companies, which encourages others to explore similar entrepreneurial paths.

EI

Elizabeth Iorns

10/03/18

@ Y Combinator

The biotech industry is experiencing a surge in startups due to unprecedented access to capital and advancements in therapeutic modalities.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

Biotech companies benefit from Y Combinator through access to capital, fundraising expertise, and interaction with diverse sectors, which can lead to unexpected advantages.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

Many biotech companies have raised significantly more capital through Y Combinator than they would have in traditional biotech venture settings, with over $200 million raised for these companies.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

There's a significant gap in funding for early-stage biotech discoveries, leading many companies to apply to Y Combinator when they have initial data suggesting a promising approach to curing diseases.

PB

Paul Buchheit

03/07/18

@ Y Combinator

Investing in things that aren't software is okay if you believe in the founder's expertise; there are many great opportunities in biotech that could lead to significant exits.

JL

Jonathan Lim

04/30/25

@ a16z

The last few years have been sobering for the biotech industry, highlighting the need to adapt quickly to survive amidst fierce competition for attention from investors, partners, and talent.